Proteomic signatures of type 2 diabetes predict the incidence of coronary heart disease.
Li Y, Li D, Lin J, Zhou L, Yang W, Yin X, Xu C, Cao Z, Wang Y.
Cardiovasc Diabetol. 2025 Mar 14;24(1):120. doi: 10.1186/s12933-025-02670-3.
Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China.
Yang T, Liu Y, Li L, Zheng Y, Wang Y, Su J, Yang R, Luo M, Yu C.
Cardiovasc Diabetol. 2022 Jun 3;21(1):93. doi: 10.1186/s12933-022-01531-7.
Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M.
N Engl J Med. 1998 Jul 23;339(4):229-34. doi: 10.1056/NEJM199807233390404.
Multiple triglyceride-derived metabolic indices and incident cardiovascular outcomes in patients with type 2 diabetes and coronary heart disease.
Tao S, Yu L, Li J, Huang L, Xue T, Yang D, Huang X, Meng C.
Cardiovasc Diabetol. 2024 Oct 14;23(1):359. doi: 10.1186/s12933-024-02446-1.
Association of C reactive protein triglyceride glucose index with mortality in coronary heart disease and type 2 diabetes from NHANES data.
Tang N, Chen X, Li H, Cheng S, Hu Y, Wang L, Zhou Q, Zhang Q, Hao J, Qi C.
Sci Rep. 2025 Jul 9;15(1):24687. doi: 10.1038/s41598-025-10184-x.
Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions.
Chen J, Yin D, Dou K.
Cardiovasc Diabetol. 2023 Jun 22;22(1):146. doi: 10.1186/s12933-023-01875-8.
Coronary Heart Disease in Type 2 Diabetes Mellitus: Genetic Factors and Their Mechanisms, Gene-Gene, and Gene-Environment Interactions in the Asian Populations.
Zarkasi KA, Abdul Murad NA, Ahmad N, Jamal R, Abdullah N.
Int J Environ Res Public Health. 2022 Jan 6;19(2):647. doi: 10.3390/ijerph19020647.
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.
Lancet. 2005 Nov 26;366(9500):1849-61. doi: 10.1016/S0140-6736(05)67667-2.
Research update on the association between SFRP5, an anti-inflammatory adipokine, with obesity, type 2 diabetes mellitus and coronary heart disease.
Wang D, Zhang Y, Shen C.
J Cell Mol Med. 2020 Mar;24(5):2730-2735. doi: 10.1111/jcmm.15023. Epub 2020 Jan 31.
Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary heart disease and type 2 diabetes mellitus: Cumulative meta-analysis.
Xie Q, Huang J, Zhu K, Chen Q.
Clin Cardiol. 2021 Jul;44(7):899-906. doi: 10.1002/clc.23613. Epub 2021 Jun 5.
